Movement Disorders CentreWestern University

MDC Publications


Last updated: Mar 2018

  1. Samotus O, Lee J, Jog M. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance. J Neurol. 2018
  2. Knowles T, Adams S, Abeyesekera A, Mancinelli C, Gilmore G, Jog M. Deep Brain Stimulation of the Subthalamic Nucleus Parameter Optimization for Vowel Acoustics and Speech Intelligibility in Parkinson's Disease. J Speech Lang Hear Res. 2018;:1-15.
  3. Samotus O, Parrent A, Jog M. Spinal cord stimulation therapy for gait dysfunction in advanced Parkinson's disease patients. Mov Disord. 2018
  4. Murgai AA, Jog MS. Neurophysiology and neurochemistry of corticobasal syndrome. J Neurol. 2018
  5. Kumar N, Murgai A, Naranian T, Jog M, Fasano A. Levodopa-carbidopa intestinal gel therapy after deep brain stimulation. Mov Disord. 2018;33(2):334-335.
  6. Samotus O, Kumar N, Rizek P, Jog M. Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics. Can J Neurol Sci. 2018;45(1):11-22.
  7. S. Memar, et al., Segmentation and detection of physical activities during a sitting task in Parkinson’s disease participants using multiple inertial sensors, J. App. (2017),
  8. Roberts A, Nguyen P, Orange JB, Jog M, Nisbet KA, Mcrae K. Differential impairments of upper and lower limb movements influence action verb processing in Parkinson disease. Cortex. 2017;97:49-59.
  9. Gilmore G, Lee DH, Parrent A, Jog M. The current state of postoperative imaging in the presence of deep brain stimulation electrodes. Mov Disord. 2017;32(6):833-838.
  10. Samotus O., Lee J., Jog M. Long-term tremor therapy for Parkinson and Essential tremor with sensor-guided botulinum toxin type A injections. PLoS ONE. 12(6):e0178670. 2017 June.
  11. Kumar N, Mendonça DA, Jog M. Teaching Video NeuroLithium-induced reversible Pisa syndrome. Neurology. 2017;88(18):e184.
  12. Delrobaei M, Baktash N, Gilmore G, Mcisaac K, Jog M. Using Wearable Technology to Generate Objective Parkinson's Disease Dyskinesia Severity Score: Possibilities for Home Monitoring. IEEE Trans Neural Syst Rehabil Eng. 2017;25(10):1853-1863.
  13. Mcgarry A, Mcdermott M, Kieburtz K, et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88(2):152-159.
  14. Kumar N, Jog M. Fahr's Disease Presenting as Late-Onset Levodopa-Responsive Parkinsonism. Can J Neurol Sci. 2017;:1-2.
  15. Kumar N, Rizek P, Jog M. Movement Disorders in 18p Deletion Syndrome: A Case Report and Review of Literature. Can J Neurol Sci. 2017;:1-3.
  16. Dayal AM, Jenkins ME, Jog MS, Kimpinski K, Macdonald P, Gofton TE. Palliative Care Discussions in Multiple System Atrophy: A Retrospective Review. Can J Neurol Sci. 2017;:1-7.
  17. Dykstra-Page, A.D., Siegel, L. & Jog, M. (in press-2017). Self-rated communication-related quality of life of individuals with oromandibular dystonia receiving botulinum toxin injections. American Journal of Speech- Language Pathology.
  18. Kumar N, Rizek P, Mohammad Y, Jog M. Pearls & Oy-sters: Niemann-Pick disease type C in a 65-year-old patient. Neurology. 2016;87(8):e79-81
  19. Rahimi F, Roberts AC, Jog M. Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study. Clin Neurol Neurosurg. 2016;150:117-124.
  20. Jackman M, Delrobaei M, Rahimi F, et al. Predicting Improvement in Writer's Cramp Symptoms following Botulinum Neurotoxin Injection Therapy. Tremor Other Hyperkinet Mov (N Y). 2016;6:410.
  21. Kumar N, Rizek P, Sadikovic B, Adams PC, Jog M. Movement Disorders Associated With Hemochromatosis. Can J Neurol Sci. 2016;43(6):801-808.
  22. McCaig CM, Adams SG, Dykstra AD, Jog M. Effect of concurrent walking and interlocutor distance on conversational speech intensity and rate in Parkinson's disease. Gait Posture. 2016 Jan; 43:132-6. doi: 10.1016/j.gaitpost.2015.09.011. Epub 2015 Sep 25. 
  23. Staudt MD, Di Sebastiano AR, Xu H, Jog M, Schmid S, Foster P, Hebb MO. Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review. Gerontology. 2015 Sep 1. 
  24. Dykstra AD, Adams SG, Jog M. Examining the relationship between speech intensity and self-rated communicative effectiveness in individuals with Parkinson's disease and hypophonia. J Commun Disord. 2015 Jul-Aug; 56:103-12
  25. Rahimi F, Samotus O, Lee J, Jog M. Effective Management of Upper Limb Parkinsonian Tremor by IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns. Tremor Other Hyperkinet Mov (N Y). 2015 Oct 30; 5:348. 
  26. Rahimi F, Debicki D, Roberts-South A, Bee C, Bapat P, Jog M. Dynamic decomposition of motion in essential and parkinsonian tremor. Can J Neurol Sci. 2015 Mar; 42(2):116-24. doi: 10.1017/cjn.2015.12. Epub 2015 Feb 23.
  27. Lebel K, Boissy P, Duval C, Jog M, Speechley M, Karelis A, Vincent C, Frank J, Edwards R. Assessing the validity of attitude and heading reference systems for biomechanical evaluation of motions – A methodological proposal. Proceedings of the International Conference on Biomedical Electronics and Devices. 2014 May: 230-237. DOI: 10.5220/0004911202300237.
  28. Modolo J., Beuter A., Cates J., Burhan A., Jog M., Thomas AW., Legros A. Relationship between motor cortex activity and resting tremor in Parkinson’s disease. Neuroscience Letters. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.
  29. Rahimi F., Bee C., Duval C., Boissy P., Edwards R., Jog M., EMAP Group. Using ecological whole body kinematics to evaluate effects of medication adjustment in Parkinson Disease. Journal of PD. In IOS press. doi: 10.3233/JPD-140370.
  30. Clark JP. Adams SG., Dykstra AD., Moodie S., Jog M., Loudness perception and speech intensity control in Parkinson’s disease. Journal of Communication Disorders. In press. 2014 August.